ESPR
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
148.26M
GET INTRADAY SIGNALS
ESPR Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
31 days until earnings call
+Compare
ESPR
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
148.26M

ESPR Price Prediction, Esperion Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ESPR Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 31, 2023

ESPR's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ESPR turned positive on March 31, 2023. Looking at past instances where ESPR's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where ESPR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on March 31, 2023. You may want to consider a long position or call options on ESPR as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ESPR advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

ESPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

ESPR moved below its 50-day moving average on March 06, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ESPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ESPR entered a downward trend on February 28, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (5.525). P/E Ratio (0.000) is within average values for comparable stocks, (47.947). ESPR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.020). ESPR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.026). P/S Ratio (1.408) is also within normal values, averaging (86.150).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ESPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ESPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

ESPR is expected to report earnings to fall 9.68% to -68 cents per share on May 02

Esperion Therapeutics ESPR Stock Earnings Reports
Q1'23
Est.
$-0.69
Q4'22
Beat
by $0.09
Q3'22
Beat
by $0.11
Q2'22
Missed
by $0.12
Q1'22
Beat
by $0.11
The last earnings report on February 21 showed earnings per share of -75 cents, beating the estimate of -84 cents. With 2.25M shares outstanding, the current market capitalization sits at 148.26M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Intra-Cellular Therapies (NASDAQ:ITCI), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.18B. The market cap for tickers in the group ranges from 246 to 80.97B. MKKGY holds the highest valuation in this group at 80.97B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 29%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 1%. INNPF experienced the highest price growth at 9,256%, while AGYTF experienced the biggest fall at -69%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 72
Price Growth Rating: 54
SMR Rating: 85
Profit Risk Rating: 93
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3891 Ranchero Drive
Phone
+1 734 887-3903
Employees
199
Web
https://www.esperion.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DTCYX14.440.18
+1.26%
BNY Mellon Sust US Equity Y
AAISX18.070.07
+0.39%
American Beacon International Eq Adv
IHORX16.690.03
+0.18%
Hartford International Opportunities R3
SGAPX22.42N/A
N/A
Virtus SGA Global Growth I
CAGSX8.18N/A
N/A
Calamos Global Sustainable Equities A

ESPR and

Correlation & Price change

A.I.dvisor tells us that ESPR and COLL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESPR and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESPR
1D Price
Change %
ESPR100%
-4.19%
COLL - ESPR
30%
Poorly correlated
-1.56%
PTPI - ESPR
29%
Poorly correlated
+1.82%
DVAX - ESPR
27%
Poorly correlated
+1.55%
VTRS - ESPR
27%
Poorly correlated
+0.63%
ANIP - ESPR
26%
Poorly correlated
+0.40%
More